Specific Pathogen Free Conditions Prevent Transthyretin Amyloidosis in Mouse Models

Overview

Journal Transgenic Res

Specialty Molecular Biology

Date 2008 Mar 22

PMID 18357510

Citations 5

Authors

Seiya Inoue

Mika Ohta

Zhenghua Li

Gang Zhao

Yutaka Takaoka

Naomi Sakashita

Kazuhisa Miyakawa

Koji Takada

Hajime Tei

Misao Suzuki

Michio Masuoka

Yoshiyuki Sakaki

Kiyoshi Takahashi

Ken-Ichi Yamamura

Affiliations

Soon will be listed here.

Abstract

Transthyretin (TTR) associated amyloidosis is an autosomal dominant disorder characterized by peripheral and autonomic neuropathy. Both genetic and environmental factors are thought to be involved in development of TTR associated amyloidosis. Previously, we demonstrated that amyloid deposition was observed in various tissues of transgenic mouse lines carrying a human mutant TTR (Met30) gene. To analyze the influence of environmental factors on TTR amyloidosis, these amyloidogenic transgenic mouse models were kept under conventional (CV) or specific pathogen free (SPF) conditions. Although the serum levels of Met30 for mice housed in the CV and SPF conditions were similar, amyloid deposition was observed in CV conditions, but not in SPF conditions. In addition, the extent of amyloid deposition in transgenic mice was dependent on duration kept under CV conditions. There were significant differences in proportion of amyloid deposition in several tissues between CV and SPF conditions. Maintenance of these mice at 30 degrees C did not induce amyloid deposition in SPF conditions. These results suggest that the SPF conditions can completely prevent amyloid deposition, and that environmental factors can affect the onset and progression even in a single gene disorder.

Citing Articles

Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability.

Carvalho E, Dias A, Coelho T, Sousa A, Alves-Ferreira M, Santos M J Neurol. 2024; 271(9):5746-5761.

PMID: 38907862 PMC: 11377651. DOI: 10.1007/s00415-024-12509-8.

Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis.

Slamova I, Adib R, Ellmerich S, Golos M, Gilbertson J, Botcher N Nat Commun. 2021; 12(1):7112.

PMID: 34876572 PMC: 8651690. DOI: 10.1038/s41467-021-27416-z.

Co-precipitation molecules hemopexin and transferrin may be key molecules for fibrillogenesis in TTR V30M amyloidogenesis.

Ohta M, Sugano A, Hatano N, Sato H, Shimada H, Niwa H Transgenic Res. 2017; 27(1):15-23.

PMID: 29288430 PMC: 5847157. DOI: 10.1007/s11248-017-0054-x.

Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amyloidosis: does the environment play a role?.

Petrakis I, Mavroeidi V, Stylianou K, Efthymiou G, Perakis K, Vardaki E Transgenic Res. 2012; 22(1):101-16.

PMID: 22806634 DOI: 10.1007/s11248-012-9632-0.

Animal models of human amyloidoses: are transgenic mice worth the time and trouble?.

Buxbaum J FEBS Lett. 2009; 583(16):2663-73.

PMID: 19627988 PMC: 2749068. DOI: 10.1016/j.febslet.2009.07.031.

References

Glenner G . Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. 1980; 302(23):1283-92. DOI: 10.1056/NEJM198006053022305. View

Conrad C, Marshall P, Talent J, Malakowsky C, Choi J, Gracy R . Oxidized proteins in Alzheimer's plasma. Biochem Biophys Res Commun. 2000; 275(2):678-81. DOI: 10.1006/bbrc.2000.3356. View

Kobayashi K, Suda T, Nan-Ya K, Sakaguchi N, Sakaguchi S, Miki I . Cytokine production profile of splenocytes derived from zymosan A-treated SKG mice developing arthritis. Inflamm Res. 2006; 55(8):335-41. DOI: 10.1007/s00011-006-5208-x. View

Ando Y, Nyhlin N, Suhr O, Holmgren G, Uchida K, El Sahly M . Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun. 1997; 232(2):497-502. DOI: 10.1006/bbrc.1996.5997. View

Saraiva M, Costa P, Goodman D . Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy, Portuguese type. J Lab Clin Med. 1983; 102(4):590-603. View

Yi S, Takahashi K, Naito M, Tashiro F, Wakasugi S, Maeda S . Systemic amyloidosis in transgenic mice carrying the human mutant transthyretin (Met30) gene. Pathologic similarity to human familial amyloidotic polyneuropathy, type I. Am J Pathol. 1991; 138(2):403-12. PMC: 1886191. View

Nagata Y, Tashiro F, Yi S, Murakami T, Maeda S, Takahashi K . A 6-kb upstream region of the human transthyretin gene can direct developmental, tissue-specific, and quantitatively normal expression in transgenic mouse. J Biochem. 1995; 117(1):169-75. DOI: 10.1093/oxfordjournals.jbchem.a124705. View

Quintas A, Saraiva M, Brito R . The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett. 1998; 418(3):297-300. DOI: 10.1016/s0014-5793(97)01398-7. View

Stangou A, Hawkins P . Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol. 2004; 17(5):615-20. DOI: 10.1097/00019052-200410000-00012. View

10.

Niraula T, Haraoka K, Ando Y, Li H, Yamada H, Akasaka K . Decreased thermodynamic stability as a crucial factor for familial amyloidotic polyneuropathy. J Mol Biol. 2002; 320(2):333-42. DOI: 10.1016/S0022-2836(02)00425-4. View

11.

Sakashita N, Ando Y, Marklund S, Nilsson P, Tashima K, Yamashita T . Familial amyloidotic polyneuropathy type I with extracellular superoxide dismutase mutation: a case report. Hum Pathol. 1998; 29(10):1169-72. DOI: 10.1016/s0046-8177(98)90433-6. View

12.

Ando Y . Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP). Med Mol Morphol. 2005; 38(3):142-54. DOI: 10.1007/s00795-005-0288-1. View

13.

Sato T, Ando Y, Seiko Susuki , Mikami F, Ikemizu S, Nakamura M . Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation. FEBS Lett. 2006; 580(2):491-6. DOI: 10.1016/j.febslet.2005.12.047. View

14.

Johnson S, Petrassi H, Palaninathan S, Mohamedmohaideen N, Purkey H, Nichols C . Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J Med Chem. 2005; 48(5):1576-87. DOI: 10.1021/jm049274d. View

15.

Glenner G . Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts). N Engl J Med. 1980; 302(24):1333-43. DOI: 10.1056/NEJM198006123022403. View

16.

Andrade C . A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952; 75(3):408-27. DOI: 10.1093/brain/75.3.408. View

17.

Takaoka Y, Tashiro F, Yi S, Maeda S, Shimada K, Takahashi K . Comparison of amyloid deposition in two lines of transgenic mouse that model familial amyloidotic polyneuropathy, type I. Transgenic Res. 1997; 6(4):261-9. DOI: 10.1023/a:1018454527309. View

18.

Tagoe C, Jacobson D, Gallo G, Buxbaum J . Mice transgenic for human TTR have the same frequency of renal TTR deposition whether maintained in conventional or specific pathogen free environments. Amyloid. 2004; 10(4):262-6. DOI: 10.3109/13506120309041744. View

19.

Hosono M, Hanada K, Toichi E, Naiki H, Higuchi K, Hosokawa T . Immune abnormality in relation to nonimmune diseases in SAM mice. Exp Gerontol. 1997; 32(1-2):181-95. DOI: 10.1016/s0531-5565(96)00070-8. View

20.

Ferrao-Gonzales A, Palmieri L, Valory M, Silva J, Lashuel H, Kelly J . Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease. J Mol Biol. 2003; 328(4):963-74. DOI: 10.1016/s0022-2836(03)00368-1. View